Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate–Risk Prostate Cancer in the US Between 2010 and 2018
Bashir Al Hussein Al Awamlh(Cornell University), Jonathan E. Shoag(University Hospitals of Cleveland), Serban Negoita(National Institutes of Health), Jeffrey J. Tosoian(Johns Hopkins University), Alec Zhu(Icahn School of Medicine at Mount Sinai), Lee Ponsky(University Hospitals of Cleveland), Daniel A. Barocas(Vanderbilt University Medical Center)
Cited by 29
Related Papers
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
Diagnosis, Evaluation and Follow-Up of Asymptomatic Microhematuria (AMH) in Adults: AUA Guideline
|The Journal of Urology|2012|487
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management
|The Journal of Urology|2022|462
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening
|The Journal of Urology|2023|368